Cara Therapeutics Inc (CARA)
0.75
-0.06
(-6.86%)
USD |
NASDAQ |
May 17, 16:00
0.75
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Cash from Financing (Quarterly): -0.685M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.685M |
December 31, 2023 | 36.48M |
September 30, 2023 | 1.116M |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.56M |
December 31, 2022 | 0.022M |
September 30, 2022 | 0.104M |
June 30, 2022 | 0.182M |
March 31, 2022 | 0.003M |
December 31, 2021 | 45.29M |
September 30, 2021 | 0.339M |
June 30, 2021 | 0.293M |
March 31, 2021 | 0.688M |
December 31, 2020 | 38.47M |
September 30, 2020 | 0.395M |
June 30, 2020 | 0.201M |
March 31, 2020 | 0.075M |
December 31, 2019 | 0.028M |
September 30, 2019 | 138.37M |
June 30, 2019 | 3.974M |
March 31, 2019 | 0.234M |
December 31, 2018 | 0.544M |
September 30, 2018 | 93.96M |
Date | Value |
---|---|
June 30, 2018 | 16.04M |
March 31, 2018 | 0.263M |
December 31, 2017 | 0.183M |
September 30, 2017 | 0.151M |
June 30, 2017 | 87.44M |
March 31, 2017 | 0.149M |
December 31, 2016 | 0.083M |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.04M |
December 31, 2015 | -0.183M |
September 30, 2015 | 75.74M |
June 30, 2015 | 0.029M |
March 31, 2015 | 0.006M |
December 31, 2014 | 0.109M |
September 30, 2014 | 0.09M |
June 30, 2014 | 0.019M |
March 31, 2014 | 57.77M |
December 31, 2013 | -0.311M |
September 30, 2013 | 0.00 |
June 30, 2013 | 7.335M |
March 31, 2013 | 1.392M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.685M
Minimum
Mar 2024
138.37M
Maximum
Sep 2019
13.29M
Average
0.316M
Median
Cash from Financing (Quarterly) Benchmarks
Stereotaxis Inc | 0.03M |
Nektar Therapeutics | 42.00M |
Avid Bioservices Inc | 0.085M |
Rigel Pharmaceuticals Inc | -2.512M |
Voyager Therapeutics Inc | 112.86M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -30.45M |
Cash from Investing (Quarterly) | 25.95M |
Free Cash Flow | -91.12M |
Free Cash Flow Per Share (Quarterly) | -0.5732 |
Free Cash Flow to Equity (Quarterly) | -31.29M |
Free Cash Flow Yield | -223.6% |